PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Glioma · Medulloblastoma · Ependymoma · Glioblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (NCI NOB Referral Group) · ncinobreferrals@mail.nih.gov

Study leads

Jing Wu, M.D.
Principal Investigator
National Cancer Institute (NCI)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

CNS Malignancies · Medulloblastoma Recurrent · ATRT Recurrent

Abroad (travel likely)RecruitingEARLY_PHASE1

Washington D.C., United States

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

Anaplastic Astrocytoma, IDH-Wildtype · Anaplastic Oligoastrocytoma · Anaplastic Oligodendroglioma

Abroad (travel likely)RecruitingPHASE2

Houston, United States

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Glioblastoma (GBM) · Newly Diagnosed Glioblastoma · GBM

Abroad (travel likely)RecruitingPHASE2

Springdale, United States · Los Angeles, United States

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

High Grade Glioma · Diffuse Intrinsic Pontine Glioma · Anaplastic Astrocytoma

Abroad (travel likely)RecruitingPHASE2

Aurora, United States · Washington D.C., United States